White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies

UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.